Lantern Pharma Inc.

LTRN

$1.87

-3.11%

2026-09-03 16:00:01 EDT-$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, ...

Price Action of LTRN

$1.87

-3.11%-$0.06

High—

Low—

52W High-60.2%

Rel. vol—

Interval

Range4.5h

Volume—SMA5SMA10

—

Lantern Pharma Inc. is a clinical-stage biotechnology firm headquartered in Dallas, Texas, dedicated to transforming oncology drug development through the strategic integration of artificial intelligence (AI), machine learning, and comprehensive genomic data analysis. Founded in 2013, the company operates with a lean team of 16 employees, focusing on precision medicine ...Lantern Pharma Inc. is a clinical-stage biotechnology firm headquartered in Dallas, Texas, dedicated to transforming oncology drug development through the strategic integration of artificial intelligence (AI), machine learning, and comprehensive genomic data analysis. Founded in 2013, the company operates with a lean team of 16 employees, focusing on precision medicine and biomarker-driven therapies to reduce the time and cost associated with traditional drug development. Their core proprietary platform, RADR (Response Algorithm for Drug Repositioning and Response), synergizes molecular data, big data analytics, and machine learning to identify patient populations most likely to respond to specific drug candidates, thereby enhancing clinical trial success rates. The company's pipeline includes three lead drug candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications. LP-100, their most advanced candidate, is currently in Phase II clinical trials for metastatic castration-resistant prostate cancer. LP-300 is being developed as a combination therapy for non-small cell lung cancer adenocarcinoma in non-smokers or never-smokers, while LP-184 is a preclinical alkylating agent designed to target DNA repair pathways in cancer cells with specific biomarkers or mutations. Financially, as a clinical-stage company with no revenue, Lantern Pharma relies on funding from public markets and potentially partnerships. With a market capitalization of approximately $35.47 million as of the latest data, the company faces typical clinical-stage risks, including high R&D expenditures and significant cash burn, reflected in negative operating cash flow and profitability metrics. Key leadership includes CEO and President Panna Sharma, who spearheads the company's vision of merging AI with precision oncology, and CFO David R. Margrave, overseeing financial strategy. The company's mission, encapsulated in its tagline 'AI for good,' aims to advance machine learning-driven drug discovery to improve patient care and ultimately crush cancer. With a committed focus on innovation and strategic drug repurposing, Lantern Pharma represents a forward-thinking approach in the biotechnology sector, targeting previously hard-to-treat cancers through advanced computational biology.ExpandCollapse

Founded

2013

Employees

CEO

Panna Sharma

Full Name

Lantern Pharma Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-456.35%

Market Cap

$0.02B

Current Ratio

1.96

WACC

6.79%

ROIC

-444.23%

Contact Information

https://www.lanternpharma.com

972 277 1136

1920 McKinney Avenue, Dallas, TX 75201

Key Metrics of LTRN

Snapshot

Latest / TTM · 6 periods

Market Cap

$23.86M

ROCE

-361.4%

EV / EBITDA

-0.92x

-86.2% YoY

FCF Yield

-59.0%

-11.5% YoY

Cash Conversion Cycle

0.0d

Current Ratio

1.96

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of LTRN

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.15x

n/a

Debt / Equity

-0.01

n/a

Current Ratio

1.96

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of LTRN

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.35 · Revenue $0.00 · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.41 · Revenue $0.00 · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.63 · Revenue $1.95M · 1 analysts
Dec 31, 2027
FY2027 · Estimated annual results
Est. EPS $-2.02 · Revenue $14.60M · 1 analysts

Recent history

Aug 14, 2026
Q2 FY2026 · Results reported
EPS $-0.57 · Revenue $0.00
View filing
May 15, 2026
Q1 FY2026 · Results reported
EPS $-0.30 · Revenue $0.00
View filing
Mar 30, 2026
FY2025 · Annual results
EPS $-1.57 · Revenue $0.00
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.39 · Revenue $0.00
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.40 · Revenue $0.00
View filing
May 15, 2025
Q1 FY2025 · Results reported
EPS $-0.42 · Revenue $0.00
View filing

Financial Statements of LTRN

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-17.1M	+17.6%	-112.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-15.7M	+12.0%	+22.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	1202.0%	+104419.6%	-172.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.40x	-58.8%	+4.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$11.0M	-56.8%	+19.1%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.57 vs -1.67	+6.0%	-0.57 vs -0.38	-50.0%
Revenue Surprise	—	—	—	—

Insider Transactions of LTRN

Acquisitions (A)

Since Jan 9, 2026

Disposals (D)

Since Jan 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
May 12, 2026	Schalop Lee Troy	director	Common stock purchase warrant (Right to Buy)	D	48,544	$2.27
May 12, 2026	Schalop Lee Troy	director	Common stock, $0.001 par value	A	48,544	$2.06
May 12, 2026	KEYSER D JEFFREY	director	Common stock, $0.001 par value	A	48,544	$2.06
May 12, 2026	KEYSER D JEFFREY	director	Common stock purchase warrant (Right to Buy)	D	48,544	$2.27
Jan 9, 2026	KEYSER D JEFFREY	director	Stock Option (Right to Buy)	A	28,844	$3.49

Earnings Call Transcript of LTRN

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We issued a press release before market opened today, summarizing our financial results and progress across the company for the second quarter ended 06/30/2026. A copy of this release is available through our website at lanternpharma.com, where you will also find a link to the slides management will be referencing on today's call. We would like to remind everyone that remarks about future expectations, performance, estimates, and prospects constitute forward looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 2 thousand. Lantern Pharma cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward looking statements, including results of clinical trials, and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements can be found in our annual report on Form 10 ks for the year ended 12/31/2025. Which is on file with the SEC and available on our website. Forward looking statements made on this conference call are as of today, August 14, 2026, and Lantern Pharma does not intend to update any of these forward looking statements to reflect events or circumstances that occur after today unless required by law. The webcast replay of the conference call and webinar will be available on Lantern's website. On today's webcast, we have Lantern Pharma's CEO, Panna Sharma and CFO. David R. Margrave. Panna will start things off with an overview of Lantern's strategy and business model, and highlight recent achievements in our operations. After which, David will discuss our financial results. This will be followed by some concluding comments from Panna. And then we will open the call for Q&A. I would now like to turn the call over to Panna Sharma. President and CEO of Lantern Pharma. Panna, please go ahead. Panna Sharma: Good morning, everyone, and thank you for joining us. To discuss our second quarter 26 results. As I have said before, AI and computationally driven approaches are now becoming central to how both large and emerging biopharma companies discover and develop drugs, but also how they allocate their resources and think about staffing their scientific teams. Today, we are at an inflection point that is actually accelerating not just for Lantern, but for how science itself will be conducted. And we are watching it happen in real trials with real patients at Lantern. The golden age of artificial intelligence in medicine is not beginning. it is actually accelerating. And this quarter, that idea has resulted in the development of a new …

Leadership Team of LTRN

5 executives

Name	Title	Compensation	Gender	Year Born	Status
Panna Sharma	President, Chief Executive Officer & Director	USD 763,750	Male	1971	Active
David R. Margrave	Chief Financial Officer & Secretary	USD 540,780	Male	1961	Active
Kishor Gopaldas Bhatia	Chief Scientific Officer & Scientific Consultant	USD 222,024	—	1955	Active
Peter L. Nara	Co-Founder & Advisor	—	—	—	Active
Marc C. Chamberlain	Chief Medical Officer of Starlight Therapeutics	—	—	—	Active

Recent News of LTRN

Seeking Alpha8/14/2026Neutral

Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript

Business Wire8/14/2026Neutral

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.

GuruFocus8/7/2026Neutral

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (âAIâ) company developing targeted and transformative cancer therapies using its proprietary

Business Wire8/7/2026Neutral

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.

GuruFocus8/3/2026Neutral

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and th

Historical Employee Count of LTRN

Current

Change

-33.33%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	16	10-K	Mar 30, 2026	View
Dec 31, 2024	24	10-K	Mar 27, 2025	View
Dec 31, 2023	21	10-K	Mar 18, 2024	View
Dec 31, 2022	22	10-K	Mar 20, 2023	View
Dec 31, 2021	14	10-K	Mar 10, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Lantern Pharma Inc.